We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App





Nova Biomedical Presents POC and Critical Care Whole Blood IVD Testing Solutions

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: Nova Biomedical is exhibiting at MEDICA 2023 at Hall 3/ C16-2 (Photo courtesy of Nova Biomedical)
Image: Nova Biomedical is exhibiting at MEDICA 2023 at Hall 3/ C16-2 (Photo courtesy of Nova Biomedical)

Nova Biomedical (Waltham, MA, USA) is presenting its range of point of care (POC) and critical care whole blood in vitro diagnostic testing solutions at MEDICA 2023.

Nova Biomedical is demonstrating the Stat Profile Prime Plus Critical Care analyzer which recently received the U.S. Food and Drug Administration (FDA) 510(k) clearance for a microcapillary sample mode. Prime Plus now performs an 11-test panel including pH, PCO2, PO2, Na, K, iCa, iMg, Cl, glucose, lactate, and hematocrit with just 90 microliters of capillary blood, or a complete 22-test profile on just 135 microliters of blood. The use of small-volume microcapillary blood collection tubes with Prime Plus eliminates sample over-draws, dead volume, and sample waste from syringe or vacuum tube devices. Prime Plus comprehensive test menu enables scheduled bundling of tests to eliminate multiple sample draws, use of multiple sample containers, and amount of blood drawn for critical care testing.

Nova Biomedical’s StatStrip Glucose Hospital Meter System is also being exhibited at MEDICA 2023. The StatStrip Glucose and StatStrip Glucose/Ketone meters are specifically designed for the detection and management of dysglycemia throughout all professional healthcare settings including critical care. Also on display at the event are the StatStrip and StatStrip Xpress2 Lactate, Hemoglobin, and Hematocrit Meter Systems which provide lactate results in only 13 seconds from a 0.6 microliter capillary blood sample, and hemoglobin and hematocrit results in 40 seconds from a 1.6 microliter capillary blood sample. StatStrip Lac/Hb/Hct meter system can connect to laboratory information systems (LIS) and electronic medical records (EMR) while the Xpress2 Lac/Hb/Hct is designed for applications that do not require connectivity.

All results offer excellent correlation to laboratory reference methods and testing with a StatStrip or Xpress2 Lac/Hb/Hct meter system is as easy as glucose self-testing. StatStrip and StatStrip Xpress2 Lac/Hb/Hct systems offer fast, point-of-care (POC) testing with single-use, disposable biosensors, tiny capillary blood samples, and easy-to-read, color display screens. The meters enable rapid, affordable lactate, hemoglobin, and hematocrit testing for any size emergency department, intensive care unit, or medical unit, as well as in pre-hospital, ambulance, and military care situations.

Related Links:
Nova Biomedical 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Orienta Tsutsugamushi Test
STANDARD Q Tsutsugamushi IgM/IgG
New
Anti-Annexin V IgG/IgM Assay
Anti-Annexin V IgG/IgM ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.